S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
NASDAQ:SGRY

Surgery Partners - SGRY Price Target & Analyst Ratings

$32.64
+0.28 (+0.87%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$31.30
$33.13
50-Day Range
$25.17
$34.00
52-Week Range
$20.46
$63.87
Volume
771,974 shs
Average Volume
606,484 shs
Market Capitalization
$2.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.33

Surgery Partners Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$42.33
29.70% Upside
High Prediction$56.00
Average Prediction$42.33
Low Prediction$35.00
TypeCurrent
1/29/22 to 1/29/23
1 Month Ago
12/30/21 to 12/30/22
3 Months Ago
10/31/21 to 10/31/22
1 Year Ago
1/29/21 to 1/29/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$42.33$40.63$57.44$58.00
Predicted Upside29.70% Upside39.93% Upside27.29% Upside27.56% Upside
Get Surgery Partners Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SGRY and its competitors with MarketBeat's FREE daily newsletter.


SGRY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SGRY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Surgery Partners Stock vs. The Competition

TypeSurgery PartnersMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.64
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside29.70% Upside1,054.33% Upside9.89% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/18/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$69.00 ➝ $56.00+75.38%
12/5/2022Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$60.00 ➝ $47.00+60.96%
11/23/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$58.00 ➝ $48.00+81.13%
11/23/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$57.00 ➝ $45.00+74.83%
11/22/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$44.00 ➝ $36.00+43.03%
11/22/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Mayo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform$55.00 ➝ $40.00+58.92%
11/16/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$35.00+28.96%
11/9/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$49.00 ➝ $38.00+54.22%
6/15/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$55.00 ➝ $36.00+16.81%
12/10/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$28.00 ➝ $35.00+22.76%
7/27/2020UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$19.00 ➝ $17.50+13.56%
(Data available from 1/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












SGRY Price Target - Frequently Asked Questions

What is Surgery Partners's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Surgery Partners stock is Moderate Buy based on the current 2 hold ratings and 5 buy ratings for SGRY. The average twelve-month price prediction for Surgery Partners is $42.33 with a high price target of $56.00 and a low price target of $35.00. Learn more on SGRY's analyst rating history.

Do Wall Street analysts like Surgery Partners more than its competitors?

Analysts like Surgery Partners more than other Medical companies. The consensus rating for Surgery Partners is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how SGRY compares to other companies.

Does Surgery Partners's stock price have much upside?

According to analysts, Surgery Partners's stock has a predicted upside of 44.02% based on their 12-month price targets.

What analysts cover Surgery Partners?

Surgery Partners has been rated by Barclays, Benchmark, Citigroup, Cowen, JPMorgan Chase & Co., Royal Bank of Canada, Stifel Nicolaus, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:SGRY) was last updated on 1/29/2023 by MarketBeat.com Staff